American National Bank raised its stake in shares of Pfizer, Inc. (NYSE:PFE) by 0.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,031 shares of the biopharmaceutical company’s stock after buying an additional 982 shares during the quarter. Pfizer comprises approximately 1.7% of American National Bank’s holdings, making the stock its 21st largest position. American National Bank’s holdings in Pfizer were worth $5,207,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sphera Funds Management LTD. purchased a new stake in Pfizer during the 1st quarter valued at approximately $13,342,000. Searle & CO. grew its holdings in Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after buying an additional 38,500 shares in the last quarter. E&G Advisors LP grew its holdings in Pfizer by 6.8% during the 1st quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock valued at $2,130,000 after buying an additional 3,940 shares in the last quarter. Insight 2811 Inc. grew its holdings in Pfizer by 3.7% during the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after buying an additional 329 shares in the last quarter. Finally, Prentiss Smith & Co. Inc. grew its holdings in Pfizer by 1.7% during the 1st quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock valued at $511,000 after buying an additional 250 shares in the last quarter. 69.09% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/17/pfizer-inc-pfe-shares-bought-by-american-national-bank.html.

In other news, insider Sally Susman sold 38,230 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ian C. Read sold 197,168 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the transaction, the chief executive officer now owns 580,318 shares of the company’s stock, valued at $19,730,812. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 464,521 shares of company stock valued at $15,813,961. Company insiders own 0.06% of the company’s stock.

A number of research analysts recently weighed in on the stock. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a report on Wednesday. BMO Capital Markets reissued a “buy” rating and issued a $37.00 target price on shares of Pfizer in a report on Thursday. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their target price for the company from $38.00 to $36.00 in a report on Thursday, July 20th. Finally, Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $37.72.

Pfizer, Inc. (PFE) traded down 1.04% during mid-day trading on Friday, hitting $35.36. The stock had a trading volume of 28,871,059 shares. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.84. The firm’s 50-day moving average price is $33.64 and its 200 day moving average price is $33.53. The company has a market cap of $210.30 billion, a PE ratio of 25.87 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.64 EPS. On average, equities research analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 94.12%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.